Tue, Jun 11, 8:29 PM (88 days ago)
Vistagen Therapeutics, Inc. filed its Form 10-K for the fiscal year ended March 31, 2024. The company, focused on developing therapies for psychiatric and neurological disorders, reported no revenue from product sales and incurred net losses of $29.4 million and $59.2 million for FY 2024 and 2023, respectively. Research and development expenses were $20.0 million in 2024, down from $44.4 million in 2023. Vistagen’s clinical-stage pipeline includes intranasal product candidates targeting social anxiety disorder, major depressive disorder, and menopausal hot flashes. The company highlighted the need for substantial additional financing to continue its development programs and indicated potential dilution risks for existing shareholders. Key risk factors include the uncertainty of regulatory approval, potential delays in clinical trials, and competition. The company plans to retain U.S. rights for its products while seeking ex-U.S. partnerships. Vistagen operates from South San Francisco, California, with 39 full-time employees.